BTMD

Insider Trading Activity: Andrew R. Heyer, a director at $BTMD, purchased 50,000 shares for approximately $197,380, increasing his holdings by 3.4%. In the past six months, all eight insider trades reported were purchases, indicating strong insider confidence in the stock.

Institutional and Analyst Sentiment: 52 institutional investors have recently increased their positions in $BTMD, while only 35 decreased theirs. Analysts have issued one buy rating with no sell ratings, suggesting a generally positive outlook on the stock.

Insider Trading Activity: Marc D Beer, a director at $BTMD, purchased 107,794 shares for approximately $417,162, increasing his holdings. In the past six months, all four insider trades reported were purchases, with no sales recorded.

Institutional and Analyst Insights: 52 institutional investors increased their positions in $BTMD stock, while 35 decreased theirs. Analysts have issued one buy rating and no sell ratings on the stock recently.

Insider Trading Activity: Bret Christensen, CEO of $BTMD, purchased 37,595 shares for approximately $145,492, marking a total of 6 insider purchases in the last 6 months with no sales reported.

Institutional and Analyst Interest: 52 institutional investors increased their holdings in $BTMD, while analysts have issued 1 buy rating and no sell ratings on the stock recently.

Board Confidence in Biote: Several members of Biote's Board of Directors and CEO Bret Christensen have purchased approximately 260,000 shares of the company's stock, reflecting their confidence in Biote's business strategy and leadership.

Biote's Mission and Market: Biote focuses on preventive healthcare through personalized hormone optimization and wellness solutions, training medical providers to address early aging indicators in an underserved market.

Board Confidence in Biote: Several board members and CEO Bret Christensen of Biote (BTMD) purchased approximately 260,000 shares, reflecting their confidence in the company's strategy and leadership.

Stock Price Target Adjustments: Analysts have lowered Biote's price target, with TD Cowen reducing it from $8 to $6, while Craig-Hallum adjusted it from $12 to $8, indicating ongoing challenges for the company.

Analyst Ratings: Truist Financial analyst Les Sulewski has maintained a Buy rating on biote (BTMD) with a price target of $7.00, while the stock currently trades at $4.00. The overall analyst consensus for biote is Strong Buy, with a price target consensus of $7.76, indicating a potential 94% upside.

Market Performance: Biote's stock has experienced a one-year high of $8.44 and a low of $3.04, with an average trading volume of 175.1K shares. Additionally, TD Cowen also supports a Buy rating with a price target of $6.00.

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

Price Target Adjustment: Roth MKM has reduced Biote's price target from $11 to $8 while maintaining a Buy rating, citing mixed quarterly results and a puzzling growth outlook despite strong EBITDA margins and free cash flow.

Financial Performance Overview: Biote reported Q4 EPS of 10 cents compared to 18 cents last year, with FY25 revenue expectations between $202 million and $208 million, below the consensus estimate of $226.16 million.

Analyst Rating and Price Target: Truist Financial analyst Les Sulewski has maintained a Buy rating on biote (BTMD) with a price target of $7.00, while the stock currently trades at $4.10. The analyst consensus for biote is a Strong Buy with a price target of $11.00.

Company Performance Overview: Biote reported a Q4 EPS of 10 cents compared to 18 cents last year, and projects FY25 revenue between $202M-$208M, which falls short of the consensus estimate of $226.16M.

Fourth Quarter and Full Year Financial Results: Biote reported a fourth quarter revenue of $49.8 million, a 9% increase from the previous year, with a net income of $3.5 million. For the full year 2024, revenue reached $197.2 million, up 6.4%, with a gross profit margin of 70.5% and a net income of $0.05 million.

Future Outlook and Strategic Initiatives: The company aims to enhance growth in 2025 by maximizing provider value, expanding its practitioner network, and improving commercial execution, projecting revenue between $202-$208 million and adjusted EBITDA of $59-64 million for the upcoming fiscal year.

Financial Results Announcement: Biote Corp. will release its fourth quarter and full year financial results on March 12, 2025, followed by a conference call at 5:00 p.m. ET to discuss the results.

Company Overview: Biote specializes in preventive health care through personalized hormone optimization and wellness solutions, aiming to address early aging conditions while training medical providers to enhance patient care.

Leadership Transition at Biote Corp: Terry Weber is retiring as CEO of Biote Corp effective February 1, 2025, transitioning to a Strategic Advisor role, while Bret Christensen has been appointed as the new CEO and Director.

Company Growth Focus: Under Weber's leadership, Biote has expanded its network of practitioners in hormone optimization, and Christensen aims to leverage his extensive experience in women's health to drive further growth and innovation in therapeutic wellness.

Analyst Rating: Alex Fuhrman from Craig-Hallum maintains a Buy rating on biote (BTMD) with a price target of $0.00, while the analyst consensus is a Strong Buy with an average price target of $10.33.

Company Performance: Biote's market cap is currently $331.5M, and it has reported steady growth in Q3 2024, although it lowered its FY24 revenue outlook.

Analyst Ratings and Price Targets: TD Cowen analyst Jonna Kim maintained a Buy rating on biote (BTMD) with a price target of $8.00, citing the company's solid financial performance and strategic business changes despite recent disruptions. Roth MKM also issued a Buy rating with a higher price target of $11.00.

Company Growth Prospects: Biote's integration with Asteria Health and transition to Amazon for dietary supplements are expected to enhance growth potential, supported by strong demand in the dietary supplement segment and improvements in clinical decision support software, which may lead to long-term competitive advantages.

New Executive Appointments: AccessHope, LLC has expanded its leadership team by appointing Dr. Yousuf Zafar as Chief Medical Officer, Peter Bridges as Chief Strategy and Growth Officer, and promoting Debra Morris to President, in response to increased demand for personalized cancer benefits.

Company Growth and Partnerships: The company has experienced significant growth, becoming a standalone entity and securing $33 million in Series B funding, while also forming partnerships with top National Cancer Institute-designated cancer centers to enhance cancer care delivery.

Biote Corp. Earnings Report: Biote Corp. reported quarterly earnings of $0.33 per share, significantly surpassing the Zacks Consensus Estimate of $0.09 and marking a 266.67% earnings surprise; revenues for the quarter were $51.38 million, aligning with estimates and showing growth from the previous year.

Stock Outlook and Industry Context: Despite underperforming compared to the S&P 500 this year, Biote Corp. holds a Zacks Rank #2 (Buy) indicating potential for future outperformance, with favorable earnings estimate revisions suggesting positive momentum ahead in the medical products industry.

Financial Performance: Biote reported a revenue of $51.4 million for Q3 2024, marking a 12.8% increase from the previous quarter, with a net income of $12.7 million and an adjusted EBITDA of $16.2 million, reflecting growth in procedure and dietary supplement revenues despite temporary disruptions from software updates and hurricane-related clinic closures.

Future Outlook: The company anticipates continued growth in procedure revenue in 2025, while adjusting its 2024 financial guidance to a revenue range of $197-$201 million and adjusted EBITDA of $58-$61 million due to ongoing impacts from recent operational challenges.

Earnings Announcement: Biote Corp. will release its third quarter financial results on November 12, 2024, followed by a conference call at 5:00 p.m. ET to discuss the results.

Company Overview: Biote specializes in preventive health care through personalized hormone optimization and wellness solutions, training medical providers to address early aging conditions while navigating various industry risks and uncertainties.

Biote (BTMD) Analyst Ratings: TD Cowen analyst Jonna Kim maintains a Buy rating on biote with a price target of $7.00, while the consensus suggests a Moderate Buy with an average target of $12.00, indicating a potential 99.3% upside.

Ardent Health Partners, Inc. (ARDT) Analyst Ratings: Bank of America Securities analyst Kevin Fischbeck assigns a Buy rating to Ardent Health Partners with a price target of $21.43, reflecting a Strong Buy consensus and a 23.9% upside from current levels.

Stock Recommendations: The article highlights four stocks—Steelcase Inc., Carriage Services, biote Corp., and Acme United Corporation—as strong investment options due to their rising cash flows and positive earnings estimates amidst economic uncertainties.

Importance of Cash Flow: It emphasizes that a company's cash position is crucial for financial health and resilience, suggesting that investors should focus on net cash flow rather than just profits when evaluating potential investments.